BiologicalDrug
VRC01 monoclonal antibody clinical trials
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2013
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2013 (2)
| Year | Studies |
|---|---|
| 2013 | 2 |
| 2015 | 2 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 5
National Institute of Allergy and Infectious Diseases (NIAID) (5)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses VRC01 monoclonal antibody is read from its arms, and is right about nine times in ten.
Testing it · 5
- Combination Therapy With VRC01 and 10-1074 in HIV-Infected Individuals Undergoing Sequential Treatment InterruptionsTerminatedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT03831945Written as VRC-HIVMAB060-00-AB (VRC01)
- VRC 601: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to HIV-Infected...CompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT01950325Written as VRC-HIVMAB060-00-AB
- Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to Healthy AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT02599896Written as VRC-HIVMAB060-00-AB (VRC01)
- Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), Administered Intravenously or Subcutaneously to Healthy AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT01993706Written as VRC-HIVMAB060-00-AB
- VRC-HIVMAB060-00-AB (VRC01) in People With Chronic HIV Infection Undergoing Analytical Treatment InterruptionCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT02471326Written as VRC-HIVMAB060-00-AB (VRC01)